By Fineline Cube 
Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co., Ltd. to jointly establish a cutting-edge next-generation sequencing (NGS) laboratory in Southern China. This collaboration aims to advance localized precision oncology diagnostics through the integration of USK Bio’s infrastructure with Gene Solutions’ expertise in AI and genomics.
Focus on MRD Monitoring
The partnership will concentrate on minimal residual disease (MRD) monitoring, leveraging Gene Solutions’ AI-powered circulating tumor DNA (ctDNA) technology. This technology is designed to meet the clinical needs of Southern China by providing early and accurate detection of cancer biomarkers.
Technological Integration
USK Bio brings to the table extensive experience in PCR-based in vitro diagnostic (IVD) product development and GMP-certified manufacturing. Gene Solutions, on the other hand, is recognized for its pioneering work in NGS oncology testing, including SPOT-MAS, Asia’s first clinically validated multi-cancer early detection solution, which has been prospectively validated in over 9,000 subjects.
Collaboration Scope
The collaboration encompasses technology transfer and personnel training, joint market development, and support for local IVD medical device regulatory filings and production. Financial details of the agreement were not disclosed.-Fineline Info & Tech